Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 9/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14790351 | 0.89 | LPL (0.44) | LPLLIPGIRAK4MTNR1AMTNR1B | |
| SCHEMBL18230142 | 0.89 | IRAK4 (0.43) | LPLLIPGIRAK4MTNR1AMTNR1B | |
| SCHEMBL20612398 | 0.85 | HTR2A (0.53) | LPLLIPGIRAK4HTR2AHTR2C | |
| SCHEMBL18239405 | 0.85 | IRAK4 (0.40) | LPLLIPGIRAK4MTNR1AMTNR1B | |
| SCHEMBL14790350 | 0.82 | LIPG (0.52) | LPLLIPG | |
| SCHEMBL29894116 | 0.81 | IRAK4 (0.46) | LPLLIPGIRAK4 | |
| SCHEMBL2215446 | 0.81 | IRAK4 (0.46) | LPLLIPGIRAK4 | |
| SCHEMBL18239357 | 0.80 | HTR6 (0.48) | LPLLIPGIRAK4 | |
| SCHEMBL760438 | 0.79 | IRAK4 (0.41) | LPLLIPGIRAK4MTNR1AMTNR1B | |
| SCHEMBL17052505 | 0.79 | IRAK4 (0.41) | LPLLIPGIRAK4HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | SELVITA S.A. (PL) | 2018-05-03 | — | — | US | disclosed |
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | SELVITA S.A. (PL) | 2018-05-03 | — | — | US | disclosed |
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | SELVITA S.A. (PL) | 2018-05-03 | — | — | US | disclosed |
| WO-2016180537-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | BRCA1, NQO2, NQO1 | LPL 4519/4885LIPG 2601/4885IRAK4 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.